

PROVINCIAL FUNDING SUMMARY

Aldesleukin (Proleukin) for In-transit Metastasis from Melanoma

pERC Recommendation: Recommends

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: July 8, 2015

This information is current as of January 11, 2018.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Under provincial consideration*		
AB	Funded	Dec 18, 2015	Intralesionally for the treatment of unresectable in-transit metastatic melanoma (ie. patients with rapidly developing in-transit metastases after surgery or patients who present with multiple in-transit metastases unsuitable for surgical resection).
SK	Funded	Sept 11, 2015	Intralesional treatment of unresectable in-transit metastatic melanoma (e.g., in patients with rapidly developing in-transit metastases after surgery or patients who present with multiple in-transit metastases unsuitable for surgical resection).
MB	Funded	Sept 9, 2015	For the first line treatment of patients with: <ul style="list-style-type: none"> • Unresectable/metastatic melanoma AND • In-transit metastases that are unsuitable for surgical resection AND/OR • In-transit metastases that developed rapidly after prior surgery. For this indication for use: <ul style="list-style-type: none"> • Aldesleukin is administered via intra-lesional injection to in-transit metastases every 2 weeks for a maximum duration of 6 doses. • Prescribing and administration of aldesleukin is restricted to designated physicians within the Cutaneous Disease Site Group.
ON	Funded	Sept 9, 2016	For treatment of in-transit metastases from melanoma in patients who have failed or are not candidates for surgery or other treatments.
NS	Funded	Dec 1, 2015	As a single agent for intralesional injection for patients with unresectable in-transit metastatic melanoma (ie patients with rapidly developing in-transit metastases after surgery or patients who present with multiple in-transit metastases unsuitable for surgical resection).

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
NB	Funded	Dec 14, 2017	As an intra-lesional injection for the treatment of patients with unresectable in-transit metastatic melanoma (i.e., patients with rapidly developing in-transit metastases after surgery or patients who present with multiple metastases unsuitable for surgical resection).
NL	Under provincial consideration*		
PEI	Under provincial consideration*		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.